Aspira Women's Health Q2 revenue $2.5M, up 23% YoY; cash burn down 46%

Aspira Women's Health Inc.

2023-Q2 EPS reported -$1.00 revenue$4,807,000

Q2 2023 revenue $2.5M (+23% YoY); OvaSuite volume 6,289 (+16%); gross margin 62% vs 47% in Q2 2022.
Cash used in operations $3.4M, down 46% from $6.3M in Q2 2022; total cash $4.5M at June 30.
Lowered H2 2023 operating cash guidance to $6–8M; received $1M debt forgiveness from Connecticut DECD.
Raised $4.3M net in July 2023 registered direct offering; total outstanding debt ~$1.6M.
Appointed Torsten Hombeck as CFO; COO/CSO Ryan Phan to depart Sept 15; new director Winfred Parnell appointed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aspira Women's Health Inc. reported second quarter ended June 30, 2023 results: revenue $2.5 million. Guidance lowered.

Period: second quarter ended June 30, 2023
Revenue: $2.5 million
Guidance: lowered
Result: reported results

Exact text from the filing

(EX-99.1) --- 2023-08-14 8K Ex 991 Exhibit 99 .1 Aspira Women’s Health ® Reports Second Quarter 2023 Financial Results Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022. OvaSuite volume of 6,289 units, an increase of 16% year-over-year Achieved cash used in operations of $3.4 million, a

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-23-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.